

Prior Authorization DRUG Guidelines

REVATIO (sildenafil)

Effective Date: 10/20/14

Date Developed: 10/14/14

Last Approval Date: 1/26/16, 1/24/17, 1/23/18

(Archived 1/22/19)

Description: Revatio inhibits phosphodiesterase in the smooth muscle of pulmonary and other vasculatures which leads to increased levels of cyclic GMP (cGMP) which, in turn, results in decreased pulmonary vascular tone.

Authorization Criteria: Treatment of pulmonary vascular hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.

Unlabeled Use: Pulmonary hypertension (WHO Group II, III, and IV); persistent pulmonary hypertension after recent left ventricular assist device placement.

Note: Per VCHCP policy, unlabeled uses are not covered unless specific information is submitted. See VCHCP Policy for Coverage of Prescription Medication for Off-Label Use.

Dosing: Oral: 5mg or 10mg three times a day; Injection: 2.5-10mg IV bolus three times a day

How Supplied: Tablets 20mg; injection 10mg/12.5 mL; oral suspension reconstituted to 10mg/mL

Contraindications/Warnings: Avoid with organic nitrates in any form; chronic use not recommended in children; carefully consider whether patients with certain underlying conditions could be adversely affected by vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension [BP less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction)

Major Adverse Reactions: Hypotension; vision and hearing loss; priapism; headache

Major Drug Interactions: Hypotensives potentiate action; ketoconazole/itraconazole/fluconazole will increase serum concentration

REFERENCES

1. Badesch DB, Abman SH, Simonneau G, et al, "Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines," *Chest*, 2007, 131(6):1917-28
2. Barst RJ, Ivy DD, Gaitan G, et al, "A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naïve Children With Pulmonary Arterial Hypertension," *Circulation*, 2012a, 125(2):324-34.
3. Barst RJ, Layton GR, Konourina I, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naïve patients with pediatric pulmonary arterial hypertension. *Eur Heart Jour*. 2012. 33:979.
4. Galie N, Ghofrani HA, Torbicki A, et al, "Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension," *N Engl J Med*, 2005, 353(20):2148-57.
5. Jackson G and Chambers J, "Sildenafil for Primary Pulmonary Hypertension: Short and Long-Term Symptomatic Benefit," *Int J Clin Pract*, 2002 56(5):397-8.
6. Karatza AA, Narang I, Rosenthal M, et al, "Treatment of Primary Pulmonary Hypertension With Oral Sildenafil," *Respiration*, 2004, 71(2):192-4.
7. Keogh AM, Jabbour A, Hayward CS, et al, "Clinical Deterioration After Sildenafil Cessation In Patients With Pulmonary Hypertension," *Vasc Health Risk Manag*, 2008, 4(5):1111-3.
8. McLaughlin VV, Archer SL, Badesch DB, et al, "ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association," *J Am Coll Cardiol*, 2009, 53(17):1573-619.
9. Simonneau G, Rubin LJ, Galie N, et al, "Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients With Pulmonary Arterial Hypertension: A Randomized Trial," *Ann Intern Med*, 2008, 149(8):521-30.
10. Toshner MR, Gopalan D, Suntharalingam J, et al, "Pulmonary Arterial Size and Response to Sildenafil in Chronic Thromboembolic Pulmonary Hypertension," *J Heart Lung Transplant*, 2010, 29(6):610-5.
11. www.uptodate.com: Sildenafil: Drug Guidelines

Revision History:

Date Approved by P&T Committee: 10/28/14; QAC 11/25/14

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19



VENTURA COUNTY
HEALTH CARE PLAN

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check ESI